Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography

To determine the area and enlargement rate (ER) of geographic atrophy (GA) in patients with age-related macular degeneration (AMD) using the spectral domain optical coherence tomography (SD-OCT) fundus image. Prospective, longitudinal, natural history study. Eighty-six eyes of 64 patients with ≥6 mo...

Full description

Saved in:
Bibliographic Details
Published in:Ophthalmology (Rochester, Minn.) Vol. 118; no. 4; p. 679
Main Authors: Yehoshua, Zohar, Rosenfeld, Philip J, Gregori, Giovanni, Feuer, William J, Falcão, Manuel, Lujan, Brandon J, Puliafito, Carmen
Format: Journal Article
Language:English
Published: United States 01.04.2011
Subjects:
ISSN:1549-4713, 1549-4713
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract To determine the area and enlargement rate (ER) of geographic atrophy (GA) in patients with age-related macular degeneration (AMD) using the spectral domain optical coherence tomography (SD-OCT) fundus image. Prospective, longitudinal, natural history study. Eighty-six eyes of 64 patients with ≥6 months of follow-up. Patients with GA secondary to AMD were enrolled in this study. Macular scans were performed using the Cirrus SD-OCT (Carl Zeiss Meditec, Dublin, CA). The areas of GA identified on the SD-OCT fundus images were quantified using a digitizing tablet. Reproducibility of these measurements was assessed and the ER of GA was calculated. The usefulness of performing square root transformations of the lesion area measurements was explored. Enlargement rate of GA. At baseline, 27% of eyes had a single area of GA. The mean total area at baseline was 4.59 mm(2) (1.8 disc areas [DA]). The mean follow-up time was 1.24 years. Reproducibility, as assessed with the intraclass correlation coefficient (ICC), was excellent on both the original area scale (ICC = 0.995) and the square root scale (ICC = 0.996). Intergrader differences were not an important source of variability in lesion size measurement (ICC = 0.999, 0.997). On average, the ER of GA per year was 1.2 mm(2) (0.47 DA; range, 0.01-3.62 mm(2)/year). The ER correlated with the initial area of GA (r = 0.45; P<0.001), but there were variable growth rates for any given baseline area. When the square root transformation of the lesion area measurements was used as a measure of lesion size, the ER (0.28 mm/yr) was not correlated with baseline size (r = -0.09; P = 0.40). In this cohort of lesions, no correlation was found between ER and length of follow-up. Square root transformation of the data helped to facilitate sample size estimates for controlled clinical trials involving GA. The SD-OCT fundus image can be used to visualize and quantify GA. Advantages of this approach include the convenience and assurance of using a single imaging technique that permits simultaneous visualization of GA along with the loss of photoreceptors and the retinal pigment epithelium that should correlate with the loss of visual function.
AbstractList To determine the area and enlargement rate (ER) of geographic atrophy (GA) in patients with age-related macular degeneration (AMD) using the spectral domain optical coherence tomography (SD-OCT) fundus image.PURPOSETo determine the area and enlargement rate (ER) of geographic atrophy (GA) in patients with age-related macular degeneration (AMD) using the spectral domain optical coherence tomography (SD-OCT) fundus image.Prospective, longitudinal, natural history study.DESIGNProspective, longitudinal, natural history study.Eighty-six eyes of 64 patients with ≥6 months of follow-up.PARTICIPANTSEighty-six eyes of 64 patients with ≥6 months of follow-up.Patients with GA secondary to AMD were enrolled in this study. Macular scans were performed using the Cirrus SD-OCT (Carl Zeiss Meditec, Dublin, CA). The areas of GA identified on the SD-OCT fundus images were quantified using a digitizing tablet. Reproducibility of these measurements was assessed and the ER of GA was calculated. The usefulness of performing square root transformations of the lesion area measurements was explored.METHODSPatients with GA secondary to AMD were enrolled in this study. Macular scans were performed using the Cirrus SD-OCT (Carl Zeiss Meditec, Dublin, CA). The areas of GA identified on the SD-OCT fundus images were quantified using a digitizing tablet. Reproducibility of these measurements was assessed and the ER of GA was calculated. The usefulness of performing square root transformations of the lesion area measurements was explored.Enlargement rate of GA.MAIN OUTCOME MEASURESEnlargement rate of GA.At baseline, 27% of eyes had a single area of GA. The mean total area at baseline was 4.59 mm(2) (1.8 disc areas [DA]). The mean follow-up time was 1.24 years. Reproducibility, as assessed with the intraclass correlation coefficient (ICC), was excellent on both the original area scale (ICC = 0.995) and the square root scale (ICC = 0.996). Intergrader differences were not an important source of variability in lesion size measurement (ICC = 0.999, 0.997). On average, the ER of GA per year was 1.2 mm(2) (0.47 DA; range, 0.01-3.62 mm(2)/year). The ER correlated with the initial area of GA (r = 0.45; P<0.001), but there were variable growth rates for any given baseline area. When the square root transformation of the lesion area measurements was used as a measure of lesion size, the ER (0.28 mm/yr) was not correlated with baseline size (r = -0.09; P = 0.40). In this cohort of lesions, no correlation was found between ER and length of follow-up. Square root transformation of the data helped to facilitate sample size estimates for controlled clinical trials involving GA.RESULTSAt baseline, 27% of eyes had a single area of GA. The mean total area at baseline was 4.59 mm(2) (1.8 disc areas [DA]). The mean follow-up time was 1.24 years. Reproducibility, as assessed with the intraclass correlation coefficient (ICC), was excellent on both the original area scale (ICC = 0.995) and the square root scale (ICC = 0.996). Intergrader differences were not an important source of variability in lesion size measurement (ICC = 0.999, 0.997). On average, the ER of GA per year was 1.2 mm(2) (0.47 DA; range, 0.01-3.62 mm(2)/year). The ER correlated with the initial area of GA (r = 0.45; P<0.001), but there were variable growth rates for any given baseline area. When the square root transformation of the lesion area measurements was used as a measure of lesion size, the ER (0.28 mm/yr) was not correlated with baseline size (r = -0.09; P = 0.40). In this cohort of lesions, no correlation was found between ER and length of follow-up. Square root transformation of the data helped to facilitate sample size estimates for controlled clinical trials involving GA.The SD-OCT fundus image can be used to visualize and quantify GA. Advantages of this approach include the convenience and assurance of using a single imaging technique that permits simultaneous visualization of GA along with the loss of photoreceptors and the retinal pigment epithelium that should correlate with the loss of visual function.CONCLUSIONSThe SD-OCT fundus image can be used to visualize and quantify GA. Advantages of this approach include the convenience and assurance of using a single imaging technique that permits simultaneous visualization of GA along with the loss of photoreceptors and the retinal pigment epithelium that should correlate with the loss of visual function.
To determine the area and enlargement rate (ER) of geographic atrophy (GA) in patients with age-related macular degeneration (AMD) using the spectral domain optical coherence tomography (SD-OCT) fundus image. Prospective, longitudinal, natural history study. Eighty-six eyes of 64 patients with ≥6 months of follow-up. Patients with GA secondary to AMD were enrolled in this study. Macular scans were performed using the Cirrus SD-OCT (Carl Zeiss Meditec, Dublin, CA). The areas of GA identified on the SD-OCT fundus images were quantified using a digitizing tablet. Reproducibility of these measurements was assessed and the ER of GA was calculated. The usefulness of performing square root transformations of the lesion area measurements was explored. Enlargement rate of GA. At baseline, 27% of eyes had a single area of GA. The mean total area at baseline was 4.59 mm(2) (1.8 disc areas [DA]). The mean follow-up time was 1.24 years. Reproducibility, as assessed with the intraclass correlation coefficient (ICC), was excellent on both the original area scale (ICC = 0.995) and the square root scale (ICC = 0.996). Intergrader differences were not an important source of variability in lesion size measurement (ICC = 0.999, 0.997). On average, the ER of GA per year was 1.2 mm(2) (0.47 DA; range, 0.01-3.62 mm(2)/year). The ER correlated with the initial area of GA (r = 0.45; P<0.001), but there were variable growth rates for any given baseline area. When the square root transformation of the lesion area measurements was used as a measure of lesion size, the ER (0.28 mm/yr) was not correlated with baseline size (r = -0.09; P = 0.40). In this cohort of lesions, no correlation was found between ER and length of follow-up. Square root transformation of the data helped to facilitate sample size estimates for controlled clinical trials involving GA. The SD-OCT fundus image can be used to visualize and quantify GA. Advantages of this approach include the convenience and assurance of using a single imaging technique that permits simultaneous visualization of GA along with the loss of photoreceptors and the retinal pigment epithelium that should correlate with the loss of visual function.
Author Puliafito, Carmen
Gregori, Giovanni
Rosenfeld, Philip J
Yehoshua, Zohar
Falcão, Manuel
Lujan, Brandon J
Feuer, William J
Author_xml – sequence: 1
  givenname: Zohar
  surname: Yehoshua
  fullname: Yehoshua, Zohar
  organization: Bascom Palmer Eye Institute, Department of Ophthalmology, Universityof Miami Miller School of Medicine, Miami, Florida, USA
– sequence: 2
  givenname: Philip J
  surname: Rosenfeld
  fullname: Rosenfeld, Philip J
– sequence: 3
  givenname: Giovanni
  surname: Gregori
  fullname: Gregori, Giovanni
– sequence: 4
  givenname: William J
  surname: Feuer
  fullname: Feuer, William J
– sequence: 5
  givenname: Manuel
  surname: Falcão
  fullname: Falcão, Manuel
– sequence: 6
  givenname: Brandon J
  surname: Lujan
  fullname: Lujan, Brandon J
– sequence: 7
  givenname: Carmen
  surname: Puliafito
  fullname: Puliafito, Carmen
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21035861$$D View this record in MEDLINE/PubMed
BookMark eNpNkElPwzAQhS1URBf4Bwj5xillnMVxj6hikyrBAc7RxJksVRIH2xHqhd9OUIvEaeaNvjdPM0s2601PjF0LWAsQ8m6_NkPta1yHMI1ArUGoM7YQSbwJ4lREs3_9nC2d2wOAlFF8weahgChRUizY95s1lSXnGtNzU_KKJolD3WiO3k4JB970HCsKLLXoqeAd6rFFywuqqCeL_tfZdBNS8K_G19wNpL3Flhemw8lsBt_oSWpTk6VeE_emO6YcLtl5ia2jq1NdsY_Hh_ftc7B7fXrZ3u8CLQF8gKBKDTIhXYCOS4ExFSpUKKnMQScUp6hFGoUYqVSEMlWQ67TM82ijokJFabhit8e9gzWfIzmfdY3T1LbYkxldpiSITZhINZE3J3LMOyqywU632UP297LwB_fxdOs
CitedBy_id crossref_primary_10_1016_j_ajo_2015_05_009
crossref_primary_10_1055_a_1002_0006
crossref_primary_10_1016_j_exer_2024_110117
crossref_primary_10_3928_23258160_20130715_06
crossref_primary_10_1016_j_ophtha_2025_01_028
crossref_primary_10_1016_j_xops_2024_100633
crossref_primary_10_3109_02713683_2015_1083588
crossref_primary_10_1097_IAE_0b013e31828d6052
crossref_primary_10_1167_tvst_14_5_5
crossref_primary_10_1007_s00417_019_04368_1
crossref_primary_10_1016_j_ajo_2023_03_012
crossref_primary_10_1007_s00417_021_05145_9
crossref_primary_10_1097_IAE_0000000000002653
crossref_primary_10_1111_opo_12675
crossref_primary_10_1016_j_ajo_2024_07_035
crossref_primary_10_1016_j_oret_2018_09_004
crossref_primary_10_3390_biomedicines11061548
crossref_primary_10_1016_j_survophthal_2019_01_014
crossref_primary_10_1097_IAE_0000000000003733
crossref_primary_10_1001_jamaophthalmol_2024_0118
crossref_primary_10_4103_tjo_TJO_D_24_00065
crossref_primary_10_1016_j_oret_2023_05_004
crossref_primary_10_1111_aos_17431
crossref_primary_10_1016_j_ajo_2016_11_002
crossref_primary_10_1167_iovs_65_14_36
crossref_primary_10_1177_24741264241305107
crossref_primary_10_1016_j_preteyeres_2024_101320
crossref_primary_10_1097_IAE_0b013e318285cbd2
crossref_primary_10_12688_f1000research_2_131_v2
crossref_primary_10_1016_j_ophtha_2018_05_028
crossref_primary_10_1111_aos_13354
crossref_primary_10_1016_j_ophtha_2017_09_028
crossref_primary_10_1016_j_ajo_2020_05_017
crossref_primary_10_1167_iovs_18_24158
crossref_primary_10_1016_j_oret_2017_02_006
crossref_primary_10_1136_bjophthalmol_2018_312643
crossref_primary_10_1007_s00417_017_3761_3
crossref_primary_10_1097_IAE_0000000000004567
crossref_primary_10_2217_imt_2022_0263
crossref_primary_10_1177_11206721241287252
crossref_primary_10_3390_jpm13010037
crossref_primary_10_1016_j_ajo_2024_03_023
crossref_primary_10_1038_s41433_020_01169_3
crossref_primary_10_1016_j_oret_2020_03_003
crossref_primary_10_1038_s41586_024_07623_6
crossref_primary_10_1159_000156477
crossref_primary_10_3928_23258160_20240418_01
crossref_primary_10_1016_j_preteyeres_2013_10_002
crossref_primary_10_1016_j_survophthal_2012_01_006
crossref_primary_10_1016_j_ophtha_2011_09_052
crossref_primary_10_1038_s41433_023_02788_2
crossref_primary_10_1111_ceo_12671
crossref_primary_10_1167_iovs_63_11_4
crossref_primary_10_1016_j_ophtha_2020_02_009
crossref_primary_10_1016_j_oret_2022_01_011
crossref_primary_10_1097_IAE_0000000000002151
crossref_primary_10_1016_j_ophtha_2020_08_027
crossref_primary_10_1097_IAE_0000000000000374
crossref_primary_10_1097_IAE_0000000000001059
crossref_primary_10_1016_j_xops_2025_100783
crossref_primary_10_1097_IAE_0000000000000249
crossref_primary_10_1167_iovs_61_6_11
crossref_primary_10_3390_nu17050771
crossref_primary_10_1007_s00417_020_04615_w
crossref_primary_10_1016_j_ophtha_2019_12_009
crossref_primary_10_1016_j_oret_2021_02_004
crossref_primary_10_5301_ejo_5000520
crossref_primary_10_1038_eye_2014_260
crossref_primary_10_1016_j_ajo_2021_11_001
crossref_primary_10_1016_j_ophtha_2013_07_013
crossref_primary_10_1371_journal_pone_0212563
crossref_primary_10_1016_j_ophtha_2012_07_076
crossref_primary_10_1136_bjophthalmol_2017_310268
crossref_primary_10_1038_s41433_021_01747_z
crossref_primary_10_2217_iim_12_4
crossref_primary_10_1016_j_oret_2020_03_020
crossref_primary_10_1016_j_ajo_2024_03_003
crossref_primary_10_1016_j_jcjo_2021_01_018
crossref_primary_10_1002_mp_13728
crossref_primary_10_1097_IIO_0000000000000512
crossref_primary_10_1016_j_oret_2022_08_007
crossref_primary_10_1016_j_ophtha_2016_04_042
crossref_primary_10_1159_000510507
crossref_primary_10_1167_iovs_65_12_25
crossref_primary_10_1007_s00417_024_06497_8
crossref_primary_10_1038_s41433_023_02497_w
crossref_primary_10_1016_j_ophtha_2013_03_029
crossref_primary_10_1007_s40123_019_00227_8
crossref_primary_10_1016_j_media_2020_101893
crossref_primary_10_1167_iovs_63_1_20
crossref_primary_10_1007_s40259_021_00481_y
crossref_primary_10_3390_jcm12113659
crossref_primary_10_1016_j_ajo_2019_12_006
crossref_primary_10_3928_23258160_20131217_01
crossref_primary_10_1016_j_ophtha_2017_08_038
crossref_primary_10_1136_bjophthalmol_2018_312430
crossref_primary_10_1167_iovs_62_13_28
crossref_primary_10_1097_IAE_0000000000002206
crossref_primary_10_1097_IAE_0000000000003017
crossref_primary_10_1016_j_ophtha_2014_08_035
crossref_primary_10_1016_j_ajo_2020_12_015
crossref_primary_10_1016_j_apjo_2025_100207
crossref_primary_10_1038_s41598_022_08919_1
crossref_primary_10_1016_j_oret_2023_06_004
crossref_primary_10_1016_j_ophtha_2016_10_002
crossref_primary_10_1111_aos_14085
crossref_primary_10_1080_14737159_2023_2208751
crossref_primary_10_1016_j_ophtha_2018_03_059
crossref_primary_10_1016_j_ophtha_2024_07_014
crossref_primary_10_1111_aos_13157
crossref_primary_10_1016_j_bcp_2025_116902
crossref_primary_10_1016_j_ophtha_2016_12_002
crossref_primary_10_1016_j_ophtha_2016_01_034
crossref_primary_10_1016_j_oret_2019_01_024
crossref_primary_10_1016_j_preteyeres_2011_06_003
crossref_primary_10_1167_iovs_64_14_31
crossref_primary_10_1097_IAE_0000000000000165
crossref_primary_10_3390_bioengineering11080849
crossref_primary_10_1186_s40942_016_0054_7
crossref_primary_10_3928_23258160_20190129_05
crossref_primary_10_1097_IAE_0000000000001766
crossref_primary_10_1136_bmjophth_2024_002105
crossref_primary_10_1016_j_oret_2018_11_013
crossref_primary_10_1016_j_xops_2025_100732
crossref_primary_10_1136_bjophthalmol_2020_317636
crossref_primary_10_1016_S0140_6736_23_01583_0
crossref_primary_10_1097_ICU_0000000000000845
crossref_primary_10_1016_j_ophtha_2015_09_016
crossref_primary_10_1016_j_preteyeres_2020_100920
crossref_primary_10_1016_j_ophtha_2013_07_047
crossref_primary_10_1007_s00417_021_05255_4
crossref_primary_10_1016_j_ajo_2021_10_032
crossref_primary_10_1097_IAE_0000000000003683
crossref_primary_10_1097_ICB_0000000000000092
crossref_primary_10_1016_j_oret_2018_03_001
crossref_primary_10_1038_s41433_024_03443_0
crossref_primary_10_1038_s41598_023_35414_y
crossref_primary_10_12688_f1000research_10664_1
crossref_primary_10_3928_23258160_20200129_01
crossref_primary_10_3928_23258160_20220914_01
crossref_primary_10_1016_j_ophtha_2020_06_019
crossref_primary_10_1016_j_ajo_2014_06_021
crossref_primary_10_1016_j_ophtha_2019_07_011
crossref_primary_10_1038_s41598_017_01733_0
crossref_primary_10_3390_jcm4020304
crossref_primary_10_1001_jamaophthalmol_2024_1269
crossref_primary_10_1167_iovs_66_4_61
crossref_primary_10_1038_s41433_025_03723_3
crossref_primary_10_1155_2017_7432739
crossref_primary_10_3928_23258160_20250214_03
crossref_primary_10_1016_j_ajo_2022_08_012
crossref_primary_10_1016_j_oret_2017_08_016
crossref_primary_10_3109_08820538_2011_577132
crossref_primary_10_1016_j_ophtha_2013_09_044
crossref_primary_10_3928_23258160_20130313_05
crossref_primary_10_1016_j_oret_2024_04_012
crossref_primary_10_1097_IAE_0000000000002480
crossref_primary_10_1007_s40135_012_0005_x
crossref_primary_10_1016_j_ajo_2018_06_020
crossref_primary_10_1016_j_oret_2019_11_011
crossref_primary_10_1016_j_ophtha_2014_06_034
crossref_primary_10_1177_11206721211035636
crossref_primary_10_1159_000505755
crossref_primary_10_1097_IAE_0000000000000460
crossref_primary_10_1097_IAE_0000000000001392
crossref_primary_10_1097_IAE_0000000000003577
crossref_primary_10_3928_23258160_20150422_03
crossref_primary_10_1016_j_xops_2023_100440
crossref_primary_10_1016_j_ajo_2020_03_042
crossref_primary_10_1097_IAE_0000000000003332
crossref_primary_10_1038_eye_2016_227
crossref_primary_10_1097_IAE_0000000000002632
crossref_primary_10_1097_IAE_0000000000001824
crossref_primary_10_1016_j_oret_2017_10_010
crossref_primary_10_1007_s00417_025_06817_6
crossref_primary_10_1016_j_oret_2018_01_019
crossref_primary_10_1186_s12886_023_02993_3
crossref_primary_10_1016_j_oret_2020_12_002
crossref_primary_10_1167_iovs_19_27475
crossref_primary_10_1159_000530418
crossref_primary_10_1007_s00347_025_02318_3
crossref_primary_10_1016_j_ophtha_2015_03_027
crossref_primary_10_1097_IAE_0b013e31828991b2
ContentType Journal Article
Copyright Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.ophtha.2010.08.018
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1549-4713
ExternalDocumentID 21035861
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NEI NIH HHS
  grantid: P30 EY014801
GroupedDBID ---
--K
.1-
.55
.FO
.GJ
0R~
123
1B1
1CY
1P~
1~5
29N
4.4
457
4G.
53G
5RE
5VS
7-5
71M
AAEDT
AAEDW
AALRI
AAQFI
AAQQT
AAQXK
AAXUO
ABCQX
ABFRF
ABJNI
ABLJU
ABMAC
ABOCM
ABWVN
ACGFO
ACGFS
ACIUM
ACNCT
ACRPL
ACVFH
ADCNI
ADMUD
ADNMO
AEFWE
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFPUW
AFRHN
AFTJW
AGCQF
AGQPQ
AIGII
AITUG
AJUYK
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BELOY
C5W
CGR
CS3
CUY
CVF
DU5
EBS
ECM
EFJIC
EFKBS
EIF
EJD
F5P
FDB
FEDTE
FGOYB
GBLVA
HVGLF
HZ~
IHE
J1W
K-O
KOM
L7B
M27
M41
MO0
N4W
N9A
NPM
NQ-
O9-
OF-
OPF
OQ~
P2P
R2-
RIG
ROL
RPZ
SDG
SEL
SES
SSZ
UHS
UNMZH
UV1
WH7
X7M
XH2
XPP
Z5R
ZGI
ZXP
7X8
ID FETCH-LOGICAL-c600t-a08fc065ecd0c4f1a4ed828a6efb0c5e47ac1732a387126780bc7fbb3983d8372
IEDL.DBID 7X8
ISICitedReferencesCount 235
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000289075200011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1549-4713
IngestDate Sat Sep 27 21:01:31 EDT 2025
Mon Jul 21 06:04:10 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c600t-a08fc065ecd0c4f1a4ed828a6efb0c5e47ac1732a387126780bc7fbb3983d8372
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/3070862
PMID 21035861
PQID 860192568
PQPubID 23479
ParticipantIDs proquest_miscellaneous_860192568
pubmed_primary_21035861
PublicationCentury 2000
PublicationDate 2011-04-01
PublicationDateYYYYMMDD 2011-04-01
PublicationDate_xml – month: 04
  year: 2011
  text: 2011-04-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Ophthalmology (Rochester, Minn.)
PublicationTitleAlternate Ophthalmology
PublicationYear 2011
References 22472261 - Ophthalmology. 2012 Apr;119(4):885-885.e3; author reply 885. doi: 10.1016/j.ophtha.2011.09.052.
References_xml – reference: 22472261 - Ophthalmology. 2012 Apr;119(4):885-885.e3; author reply 885. doi: 10.1016/j.ophtha.2011.09.052.
SSID ssj0006634
Score 2.4868414
Snippet To determine the area and enlargement rate (ER) of geographic atrophy (GA) in patients with age-related macular degeneration (AMD) using the spectral domain...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 679
SubjectTerms Aged
Aged, 80 and over
Disease Progression
Female
Fluorescein Angiography
Follow-Up Studies
Geographic Atrophy - classification
Geographic Atrophy - diagnosis
Geographic Atrophy - etiology
Humans
Macular Degeneration - classification
Macular Degeneration - complications
Macular Degeneration - diagnosis
Male
Middle Aged
Observer Variation
Photography
Prospective Studies
Reproducibility of Results
Tomography, Optical Coherence
Title Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography
URI https://www.ncbi.nlm.nih.gov/pubmed/21035861
https://www.proquest.com/docview/860192568
Volume 118
WOSCitedRecordID wos000289075200011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1Fe8sBqiOM0cSaEEBUDrToA6hY5fpAOiUMbGPntnJ0UJsTAkilWIvt8993dd3cIXeokTrVSKZEhZSRSuSGpSRUBS6SDOAyS3JMxXx6T8ZhPp-mk4-YsOlrlUid6Ra2sdDHyax47MDKI-U39RtzQKJdc7SZorKIeAyTjhDqZ_jQLB2Pqk8rgAhHQwWxZOefpXbYumkJ03C5-FVD-O8b0tma4_c-_3EFbHcjEt61U7KIVXe2hjVGXRt9HnxPHymo7cmBr8Gs7Cb2YSexC47DzeFZh0DTEl7pohUvh-apY6Vffp9odJ56V8IrCLpSLfcXmHD6qbClgsa19kBxLW7QFhbixZdce-wA9D--f7h5IN4iBSMBDDREBNxKwipYqkJGhItIKPDURa5MHcqCjREiasFAwcL9CMH9BLhOT5yzlTIEHHB6itcpW-hhhqjVPpOv6F6cRoDVBcxnlDI4vTjk1uo_wcmMzEHSXvRCVtu-L7Htr--ioPZysbhtyZOC2sgGP6cnfi0_RZhsVdtybM9QzcMn1OVqXH81sMb_wAgTP8WT0Bfhc0vs
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Progression+of+geographic+atrophy+in+age-related+macular+degeneration+imaged+with+spectral+domain+optical+coherence+tomography&rft.jtitle=Ophthalmology+%28Rochester%2C+Minn.%29&rft.au=Yehoshua%2C+Zohar&rft.au=Rosenfeld%2C+Philip+J&rft.au=Gregori%2C+Giovanni&rft.au=Feuer%2C+William+J&rft.date=2011-04-01&rft.issn=1549-4713&rft.eissn=1549-4713&rft.volume=118&rft.issue=4&rft.spage=679&rft_id=info:doi/10.1016%2Fj.ophtha.2010.08.018&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-4713&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-4713&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-4713&client=summon